Keytruda and Silodosin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keytruda (pembrolizumab) and Silodosin (silodosin). Common drug interactions include flank pain among females and hypertension among males.

The phase IV clinical study analyzes what interactions people have when they take Keytruda and Silodosin. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Silodosin?

Silodosin has active ingredients of silodosin. eHealthMe is studying from 3,839 Silodosin users. Check the latest studies of Silodosin.

On Jul, 25, 2026

48 people who take Keytruda and Silodosin together, and have interactions are studied.

Keytruda and Silodosin drug interactions.

What are the common drug interactions of Keytruda and Silodosin, by gender? *:

female:

Flank pain (a distressing sensation experienced around the lower back and the upper abdomen)
Hyperkalaemia (damage to or disease of the kidney)
Malignant neoplasm progression (cancer tumour came back)

male:

Hypertension (high blood pressure)
Decreased appetite
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
Weight decreased
Vitamin b1 deficiency
Wernicke's encephalopathy (ocular disturbances, changes in mental state, unsteady stance and gait due to deficiency of vit.b1)
Asthenia (weakness)
Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
Malignant neoplasm progression (cancer tumour came back)
Meningitis listeria (a bacterial infection of the membranes covering the brain and spinal cord (meninges))

What are the common drug interactions of Keytruda and Silodosin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Hepatic failure (liver failure)
Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
Hepatorenal syndrome (renal failure in patients with advanced chronic liver disease)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
Death
Erythema (redness of the skin)

60+:

Hypertension (high blood pressure)
Malignant neoplasm progression (cancer tumour came back)
Diarrhoea
Vomiting
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
Renal impairment (severely reduced kidney function)
Asthenia (weakness)
Meningitis listeria (a bacterial infection of the membranes covering the brain and spinal cord (meninges))
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

High Blood Pressure: 11 people, 22.92%
Enlarged Prostate: 10 people, 20.83%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 9 people, 18.75%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 6 people, 12.50%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 5 people, 10.42%
Nausea (feeling of having an urge to vomit): 5 people, 10.42%
Renal Cell Carcinoma Stage Iv (stage iv renal cell cancer have cancer that has spread to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes): 4 people, 8.33%
Spinal Stenosis (narrowing of spinal column): 3 people, 6.25%
Malignant Neoplasm Of Renal Pelvis (cancer tumour of ureter): 3 people, 6.25%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 3 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and Silodosin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously